Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Gross Profit (2020 - 2022)

Immuneering (IMRX) has 3 years of Gross Profit data on record, last reported at $455.0 in Q4 2022.

  • For Q4 2022, Gross Profit rose 102.74% year-over-year to $455.0; the TTM value through Sep 2023 reached $455.0, down 99.68%, while the annual FY2022 figure was $158830.0, 82.86% down from the prior year.
  • Gross Profit reached $455.0 in Q4 2022 per IMRX's latest filing, down from $19037.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $367568.0 in Q3 2020 and bottomed at -$16630.0 in Q4 2021.
  • Average Gross Profit over 3 years is $169705.9, with a median of $168312.5 recorded in 2020.
  • The widest YoY moves for Gross Profit: up 102.74% in 2022, down 92.76% in 2022.
  • A 3-year view of Gross Profit shows it stood at $367568.0 in 2020, then plummeted by 104.52% to -$16630.0 in 2021, then surged by 102.74% to $455.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $455.0 in Q4 2022, $19037.0 in Q3 2022, and $46486.0 in Q2 2022.